Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate

Journal of Pharmaceutical Sciences

Volumn 93, Issue 6, 2004, Pages 1431-1439

  Raoof, Araz A ^a,c   Chiu, Peter ^a   Ramtoola, Zeibun ^a   Cumming, Iain K ^a   Teng, Chingleou ^b   Weinbach, Susan P ^b   Hardee, Greg E ^b   Levin, Arthur A ^b   Geary, R S ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ISIS PHARMACEUTICALS   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Absorption enhancer; Antisense; Bioavailability; Multidose tolerability; Sodium caprate

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DECANOATE SODIUM; ISIS 104838; MESSENGER RNA; PENETRATION ENHANCING AGENT; PHOSPHOROTHIOIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG METABOLISM; DRUG SCREENING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FEMALE; IMMUNOTHERAPY; IN VIVO STUDY; KIDNEY PARENCHYMA; LIVER PARENCHYMA; LYMPH NODE; MALE; MULTIPLE DRUG DOSE; NONHUMAN; PREFORMULATION; SPLEEN; TABLET FORMULATION; TISSUE DISTRIBUTION; TISSUE TYPES;

EID: 2642556483     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20051     Document Type: Article

References (27)

1. Crooke ST. 1998. Antigens therapeutics. In: Thomas JA, editor. Biotechnology and safety assessment. Philadelphia: Taylor and Francis, pp 23-60.
2. Bennett CF. 1999. Antisense oligonucleotide therapeutics. Expert Opin Invest Drugs 8:237-253.
3. Bennett CF, Butler M, Cook PD, Geary RS, Levin AA, Mehta R, Teng CL, Deshmukh H, Tillman L, Hardee G. 2000. Antisense oligonucleotide-based therapeutics. In: Templeton NS, Lasic DD, editors. Gene therapy. New York: Marcel Dekker.
4. Stixt G. 1998. Shutting down a gene. Antigens drug wins approval. Sci Am 279:46.
5. Dressman JB, Bass P, Ritschel WA, Friend DR, Rubinstein A, Ziv E. 1993. Gastrointestinal parameters that influence oral medications. J Pharm Sci 82:857-872.
6. Geary RS, Khatsenko O, Bunket K, Crooke R, Moore M, Burkin T, Truong L, Sasmor H, Levin AA. 2001. Absolute bioavailability of 2′ -O-(2-methoxyethyl)-modified antigens oligonucleotides following intraduodenal instillation in rats. J Pharmacol Exp Ther 296:898-904.
7. Aungst BJ. 2000. Intestinal permeation enhancers. J Pharm Sci 89:429-442.
8. Ishizawa T, Hayashi M, Awazu S. 1987. Enhancement of jejunal and colonic absorption of fosfomycin by promoters in the rat. J Pharm Pharmacol 39:892-895.
9. Lindmark T, Soderholm JD, Olaison G, Alvan G, Ocklind G, Artursson P. 1997. Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Pharm Res 14:930-935.
10. Beutler BA. 1999. The role of tumor necrosis factor in health and disease. J Rheumatol 57(Suppl): 16-21.
11. Ferrari R. 1999. The role of TNF in cardiovascular disease. Pharmacol Res 40:97-105.
12. Jacobs RF, Tabor DR. 1990. The immunology of sepsis and meningitis-cytokine biology. Scand J Infect Dis 73(Suppl):7-15.
13. Tracey KJ, Cerami A. 1993. Tumor necrosis factor: An updated review of its biology. Crit Care Med 21(Suppl):S415-S422.
14. Zhao Q, Song X, Waldschmidt T, Fisher E, Krieg AM. 1996. Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation. Blood 88:1788-1795.
15. Butler M, Stecker K, Bennett CF. 1997. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 77:379-388.
16. Levin AA. 1999. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1489:69-84.
17. Geary RS, Matson J, Levin AA. 1999. A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue. Anal Biochem 274:241-248.
18. Leeds JM, Graham MJ, Truong L, Cummins LL. 1996. Quantitation of phosphorothioate oligonucelotides in human plasma. Anal Biochem 235:36-43.
19. Raoof AA, Ramtoola Z, McKenna B, Yu RZ, Hardee G, Geary RS. 2002. Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci 17:131-138.
20. Jenson RG, Ferris AM, Lammi-Keefe CJ. 1991. The composition of milk fat. J Dairy Sci 74:3228-3243.
21. Dressman JB. 1986. Comparison of canine and human gastrointestinal physiology. Pharm Res 3:123-131.
22. Yu RZ, Geary RS, Leeds JM, Watanabe T, Fitchett JR, Matson JE, Mehta R, Hardee GR, Templin MV, Huang K, Newman MS, Quinn Y, Uster P, Zhu G, Working PK, Horner M, Nelson J, Levin AA. 1999. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Haras encapsulated in stealth liposomes. Pharm Res 16:1309-1315.
23. Yu RZ, Geary RS, Leeds JM, Watanabe T, Moore M, Fitchett J, Matson J, Burckin T, Templin MV, Levin AA. 2001. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 90:182-193.
24. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TK, Yu RZ, Tami JA, Dorr AF. 2002. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antigens oligonucleotide targeting tumour necrosis factor-alpha. J Pharmacol Exp Ther 303:1334-1343.
25. Anderberg EK, Lindmark T, Artursson P. 1993. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm Res 10:857-864.
26. Quan YS, Hattori K, Lundborg E, Fujita T, Murakami M, Muranishi S, Yamamoto A. 1998. Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers. Biol Pharm Bull 21:615-620.
27. Chao AC, Nguyen JV, Broughall M, Griffin A, Fix JA, Daddona PE. 1999. In vitro and in vivo evaluation of effects of sodium caprate on enteral peptide absorption and on mucosal morphology. Int J Pharm 191:15-24.